Lepage Philippe, Vergison Anne
Université Libre de Bruxelles, Department of Pediatrics, Queen Fabiola University Children's Hospital, 15, Avenue JJ Crocq, 1020 Brussels, Belgium.
Expert Opin Biol Ther. 2007 Dec;7(12):1881-92. doi: 10.1517/14712598.7.12.1881.
Rotaviruses are the most common enteric pathogens to cause acute diarrhoea in infants and young children throughout the world. Two new live, orally administered vaccines (Rotarix and RotaTeq) that provide protection against rotavirus infections are now available and have been licensed in many countries in Europe, North and Latin America. Two recent large clinical trials have demonstrated that their efficacy, immunogenicity and safety, including absence of vaccine-associated intussusception in young infants, are remarkably similar. The protection against severe rotavirus gastroenteritis extends into the second year of follow up for both vaccines. Rotarix and RotaTeq vaccines can be coadministered with routine childhood vaccines. However, more data on the efficacy of these two new vaccines in low-income nations are needed, particularly in Asia and Africa, before global inclusion of rotavirus vaccines into national immunisation programmes can be recommended.
轮状病毒是全球引起婴幼儿急性腹泻最常见的肠道病原体。两种新型口服活疫苗（Rotarix和RotaTeq）可预防轮状病毒感染，现已上市，并在欧洲、北美和拉丁美洲的许多国家获得许可。最近的两项大型临床试验表明，它们的疗效、免疫原性和安全性，包括在幼儿中不存在疫苗相关的肠套叠，都非常相似。两种疫苗对严重轮状病毒胃肠炎的保护作用都可延续到随访的第二年。Rotarix和RotaTeq疫苗可与儿童常规疫苗同时接种。然而，在全球建议将轮状病毒疫苗纳入国家免疫规划之前，还需要更多关于这两种新疫苗在低收入国家，特别是亚洲和非洲的疗效数据。
